dr. luke discusses the combination of epacadostat and pembrolizumab in melanoma
Published 7 years ago • 315 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
2:00
exploring the combination of epacadostat and pembrolizumab in urothelial carcinoma
-
1:04
dr. luke on the combination of pembrolizumab and t-vec for melanoma
-
1:31
dr. luke discusses pd-1 inhibitors for melanoma
-
1:57
dr. luke discusses the controversy surrounding ipilimumab/nivolumab combo in melanoma
-
1:09
dr. jason luke talks about advances in how melanoma is diagnosed
-
1:50
dr. hamid on epacadostat plus pembrolizumab in advanced melanoma
-
1:41
dr. luke discusses combination approaches on horizon in melanoma
-
1:01
dr. luke on the future of combination therapy in melanoma
-
1:30
dr. jason luke on sequencing targeted and immunotherapy agents in braf melanoma
-
1:06
dr. luke on the future role of immunotherapy combinations in melanoma
-
1:42
dr. jason luke describes results from the phase iii combi-d trial
-
0:55
dr. luke discusses pd-1 plus ido inhibitors in melanoma
-
0:54
interim analysis of a study exploring indoximod/pembrolizumab combo in melanoma
-
1:07
dr. luke discusses noncutaneous melanoma
-
0:59
dr. luke on treatment options in metastatic melanoma
-
1:28
dr. puzanov on sequencing targeted therapy and immunotherapy in melanoma
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
2:32
dr. hamid on a retrospective analysis of pembrolizumab in melanoma